Capital International Sarl Buys 12,412 Shares of Abbott Laboratories $ABT

Capital International Sarl increased its position in shares of Abbott Laboratories (NYSE:ABT) by 4.2% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 308,147 shares of the healthcare product maker’s stock after purchasing an additional 12,412 shares during the quarter. Capital International Sarl’s holdings in Abbott Laboratories were worth $41,273,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of ABT. Norges Bank acquired a new stake in shares of Abbott Laboratories during the 2nd quarter worth approximately $3,026,180,000. Laurel Wealth Advisors LLC boosted its holdings in shares of Abbott Laboratories by 13,347.0% in the 2nd quarter. Laurel Wealth Advisors LLC now owns 6,056,934 shares of the healthcare product maker’s stock valued at $823,804,000 after purchasing an additional 6,011,891 shares in the last quarter. Vanguard Group Inc. increased its stake in shares of Abbott Laboratories by 1.8% in the 2nd quarter. Vanguard Group Inc. now owns 172,800,851 shares of the healthcare product maker’s stock valued at $23,502,644,000 after purchasing an additional 2,977,715 shares during the last quarter. First Trust Advisors LP raised its holdings in shares of Abbott Laboratories by 180.7% during the 2nd quarter. First Trust Advisors LP now owns 3,063,443 shares of the healthcare product maker’s stock worth $416,659,000 after buying an additional 1,972,097 shares in the last quarter. Finally, Capital International Investors lifted its position in shares of Abbott Laboratories by 2.5% during the 3rd quarter. Capital International Investors now owns 61,614,739 shares of the healthcare product maker’s stock worth $8,251,974,000 after buying an additional 1,478,076 shares during the last quarter. 75.18% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

ABT has been the subject of several research analyst reports. Evercore lowered their target price on Abbott Laboratories from $144.00 to $138.00 and set an “outperform” rating for the company in a research note on Friday, January 23rd. Piper Sandler decreased their price target on shares of Abbott Laboratories from $150.00 to $135.00 and set an “overweight” rating on the stock in a report on Friday, January 23rd. BTIG Research dropped their price objective on shares of Abbott Laboratories from $145.00 to $140.00 and set a “buy” rating for the company in a research note on Tuesday, February 17th. The Goldman Sachs Group decreased their target price on shares of Abbott Laboratories from $152.00 to $140.00 and set a “buy” rating on the stock in a research note on Friday, January 23rd. Finally, William Blair raised Abbott Laboratories to a “strong-buy” rating in a report on Thursday, November 20th. Two investment analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $136.37.

Insider Activity at Abbott Laboratories

In other Abbott Laboratories news, EVP Mary K. Moreland sold 613 shares of the stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $115.58, for a total transaction of $70,850.54. Following the completion of the sale, the executive vice president directly owned 104,291 shares in the company, valued at approximately $12,053,953.78. This trade represents a 0.58% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, VP John A. Jr. Mccoy sold 585 shares of the firm’s stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $115.58, for a total value of $67,614.30. Following the sale, the vice president directly owned 24,628 shares of the company’s stock, valued at $2,846,504.24. This represents a 2.32% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 3,055 shares of company stock valued at $353,097 over the last 90 days. 0.46% of the stock is owned by company insiders.

Abbott Laboratories Stock Up 2.9%

NYSE:ABT opened at $112.69 on Tuesday. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.58 and a quick ratio of 1.18. Abbott Laboratories has a one year low of $105.27 and a one year high of $139.15. The firm’s 50 day simple moving average is $115.86 and its 200 day simple moving average is $124.44. The company has a market cap of $195.82 billion, a PE ratio of 30.29, a P/E/G ratio of 1.74 and a beta of 0.74.

Abbott Laboratories (NYSE:ABT) last released its quarterly earnings results on Thursday, January 22nd. The healthcare product maker reported $1.50 earnings per share (EPS) for the quarter, meeting the consensus estimate of $1.50. Abbott Laboratories had a net margin of 14.72% and a return on equity of 17.73%. The firm had revenue of $11.46 billion during the quarter, compared to the consensus estimate of $11.80 billion. During the same quarter last year, the firm earned $1.34 earnings per share. The company’s revenue for the quarter was up 4.4% on a year-over-year basis. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. On average, research analysts anticipate that Abbott Laboratories will post 5.14 earnings per share for the current year.

Abbott Laboratories Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, May 15th. Shareholders of record on Wednesday, April 15th will be issued a dividend of $0.63 per share. The ex-dividend date is Wednesday, April 15th. This represents a $2.52 annualized dividend and a yield of 2.2%. Abbott Laboratories’s dividend payout ratio (DPR) is presently 67.74%.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.